Fagerberg B, Wiklund O, Agewall S, Camejo G, Wikstrand R J
Department of Medicine, Sahlgrenska University Hospital, Göteberg University, Sweden.
Eur J Clin Invest. 1996 Nov;26(11):960-5. doi: 10.1046/j.1365-2362.1996.2030543.x.
The purpose of this work was to examine in an open, randomized parallel-group study whether an intervention programme directed towards hypercholesterolaemia, smoking and diabetes mellitus in treated hypertensive men was associated with less complex formation between low-density lipoprotein (LDL) and human arterial proteoglycans than was the case with usual care. The intervention consisted mainly of non-pharmacological treatment, but drug therapy could be instituted to achieve the treatment goals in the intervention group. The intervention programme was associated with a significant reduction in body mass index, and 46% of the patients were on lipid-lowering medication at the follow-up examination. The net differences were (intervention--usual care): change in serum LDL-cholesterol, -0.48 mmol L-1 (95% confidence interval -0.84 to -0.11 mmol L-1), precipitated LDL-cholesterol, -5.5 micrograms (95% CI -9.0 to -1.1 micrograms). The latter remained after adjustment for the difference in serum LDL-cholesterol between groups. Our conclusion is that the multifactorial risk factor treatment programme was associated with a reduced tendency of LDL to form complexes with human arterial proteoglycans.
本研究旨在通过一项开放性随机平行组研究，探讨针对接受治疗的高血压男性患者的高胆固醇血症、吸烟和糖尿病实施干预方案，与常规治疗相比，是否能减少低密度脂蛋白（LDL）与人体动脉蛋白聚糖之间形成复合物的情况。干预措施主要包括非药物治疗，但在干预组中，可采用药物治疗以实现治疗目标。干预方案与体重指数显著降低相关，在随访检查时，46%的患者正在服用降脂药物。净差异为（干预组 - 常规治疗组）：血清LDL胆固醇变化为 -0.48 mmol/L（95%置信区间为 -0.84至 -0.11 mmol/L），沉淀的LDL胆固醇为 -5.5微克（95%置信区间为 -9.0至 -1.1微克）。在对两组间血清LDL胆固醇差异进行校正后，后者依然存在。我们的结论是，多因素风险因素治疗方案与LDL与人体动脉蛋白聚糖形成复合物的趋势降低相关。
